Literature DB >> 11961399

Acute renal failure in bone marrow transplant patients admitted to the intensive care unit.

Isabelle Létourneau1, Marc Dorval, Robert Bélanger, Martin Légaré, Louise Fortier, Martine Leblanc.   

Abstract

BACKGROUND/AIMS: Review of bone marrow transplant (BMT) cases admitted to our intensive care unit (ICU) and to compare co-morbidity and outcome of BMT patients developing or not developing acute renal failure (ARF).
METHODS: A case review of BMT patients admitted to the ICU (a 16-bed medico-surgical ICU in a tertiary care teaching institution) over a 4-year period.
RESULTS: Between January 1994 and December 1998, 57 among 441 BMT patients (12.9%) were admitted to the ICU, mainly for respiratory distress (58%) and hypotension (32%). Forty-two patients (73.7%) presented ARF as defined as a doubling of serum creatinine. Compared to the 15 other patients, ARF patients had a higher APACHE II score (30 +/- 8 vs. 25 +/- 7, p < 0.05). For ARF vs. non-ARF patients, there was no difference in age (43.8 +/- 10.8 vs. 44.3 +/- 11.1 years), in requirement for mechanical ventilation (76 vs. 73%) and vasopressors (69 vs. 60%), and in prevalence of graft-versus-host disease (19 vs. 13%) or neutropenia (69 vs. 67%), but the prevalence of sepsis (83 vs. 60%) and liver failure (69 vs. 40%) was higher. Maximum serum bilirubin was markedly increased in ARF compared to non-ARF patients (p < 0.005). For both subgroups, no difference in the administration of potential nephrotoxic agents was identified. Usually, ARF was considered multifactorial by clinicians, with ATN being the most frequent diagnosis (55%). Maximum serum creatinine reached a mean of 330 +/- 130 micromol/l. In 74% of cases, ARF occurred concomitantly or after admission to the ICU. Oligoanuria was present in 38%, whereas polyuria was observed in 17%. Fourteen ARF patients (33%) required dialytic support. Mortality rates were significantly different in ARF vs. non-ARF patients (88 vs. 60%, p < 0.05). Predictive factors for the development of ARF were liver failure (odds ratio (OR) 5.9), low serum albumin (OR 1.2) and APACHE II score (OR 1.1), whereas variables predictive of mortality were mechanical ventilation (OR 14.8), ARF (OR 5.8), liver failure (OR 3.7), and APACHE II score (OR 1.2).
CONCLUSIONS: This study confirms that ARF in BMT patients admitted to the ICU is frequent, multifactorial, related to liver failure, and that its development has a negative impact on outcome. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 11961399     DOI: 10.1159/000054728

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  10 in total

1.  Scavenger Receptor BI Protects against Septic Death through Its Role in Modulating Inflammatory Response.

Authors:  Ling Guo; Zhiqing Song; Mengting Li; Qingan Wu; Dan Wang; Hong Feng; Philip Bernard; Alan Daugherty; Bin Huang; Xiang-An Li
Journal:  J Biol Chem       Date:  2009-06-02       Impact factor: 5.157

Review 2.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Authors:  Jason A Coppell; Paul G Richardson; Robert Soiffer; Paul L Martin; Nancy A Kernan; Allen Chen; Eva Guinan; Georgia Vogelsang; Amrita Krishnan; Sergio Giralt; Carolyn Revta; Nicole A Carreau; Massimo Iacobelli; Enric Carreras; Tapani Ruutu; Tiziano Barbui; Joseph H Antin; Dietger Niederwieser
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-18       Impact factor: 5.742

3.  Continuous venovenous haemofiltration in cancer patients with renal failure: a single-centre experience.

Authors:  T Berghmans; A P Meert; E Markiewicz; J P Sculier
Journal:  Support Care Cancer       Date:  2004-01-28       Impact factor: 3.603

4.  Should dialysis be offered to cancer patients with acute kidney injury?

Authors:  Michael Darmon; Guillaume Thiery; Magali Ciroldi; Raphaël Porcher; Benoît Schlemmer; Élie Azoulay
Journal:  Intensive Care Med       Date:  2007-03-07       Impact factor: 17.440

5.  Hydroxyfasudil-mediated inhibition of ROCK1 and ROCK2 improves kidney function in rat renal acute ischemia-reperfusion injury.

Authors:  Dominik Kentrup; Stefan Reuter; Uta Schnöckel; Alexander Grabner; Bayram Edemir; Hermann Pavenstädt; Otmar Schober; Michael Schäfers; Eberhard Schlatter; Eckhart Büssemaker
Journal:  PLoS One       Date:  2011-10-21       Impact factor: 3.240

6.  Continuous Renal Replacement Therapy for Acute Renal Failure in Patients with Cancer: A Well-Tolerated Adjunct Treatment.

Authors:  Rebecca Fischler; Anne-Pascale Meert; Jean-Paul Sculier; Thierry Berghmans
Journal:  Front Med (Lausanne)       Date:  2016-08-03

Review 7.  Hypoalbuminemia and acute kidney injury: a meta-analysis of observational clinical studies.

Authors:  Christian J Wiedermann; Wolfgang Wiedermann; Michael Joannidis
Journal:  Intensive Care Med       Date:  2010-06-02       Impact factor: 17.440

8.  Critically ill cancer patient's resuscitation: a Belgian/French societies' consensus conference.

Authors:  Anne-Pascale Meert; Sebastian Wittnebel; Stéphane Holbrechts; Anne-Claire Toffart; Jean-Jacques Lafitte; Michael Piagnerelli; France Lemaitre; Olivier Peyrony; Laurent Calvel; Jean Lemaitre; Emmanuel Canet; Alexandre Demoule; Michael Darmon; Jean-Paul Sculier; Louis Voigt; Virginie Lemiale; Frédéric Pène; David Schnell; Etienne Lengline; Thierry Berghmans; Laurence Fiévet; Christiane Jungels; Xiaoxiao Wang; Ionela Bold; Aureliano Pistone; Adriano Salaroli; Bogdan Grigoriu; Dominique Benoit
Journal:  Intensive Care Med       Date:  2021-09-20       Impact factor: 17.440

Review 9.  Invasive mechanical ventilation as a risk factor for acute kidney injury in the critically ill: a systematic review and meta-analysis.

Authors:  Johannes P C van den Akker; Mahamud Egal; A B Johan Groeneveld
Journal:  Crit Care       Date:  2013-05-27       Impact factor: 9.097

10.  The 28-day survive for critically ill cancer patients undergoing continuous renal replacement with postoperative acute kidney injure: a retrospective study of 86 cases.

Authors:  Zhen-Nan Yuan; Hai-Jun Wang; Shi-Ning Qu; Chu-Lin Huang; Hao Wang; Hao Zhang; Quan-Hui Yang; Xue-Zhong Xing
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.